Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Oct 25, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell

This study aimed to investigate the outcomes of a second hematopoietic stem cell transplant (HSCT) after reduced-intensity conditioning (RIC) for patients with leukemia or lymphoma.  

This study concluded that this treatment path is feasible and a good treatment alternative for these patients.  

Some background

Allogenic hemopoietic stem cell transplantation (allo-HSCT) is the transfer of stem cells from a matched donor to a cancer patient. HSCT can replace diseased blood cells destroyed by cancer treatment. HSCT can also be autologous (auto-HSCT) where the stem cells come from the patients themselves.  

Relapse and graft failure after allo- or auto-HSCT are serious and often fatal events. A second HSCT can be lifesaving but there is little information available on this.  

Methods & findings

This study involved 27 patients with leukemia or lymphoma who received an outpatient allo-HSCT after an initial auto-HSCT (12 patients) or allo-HSCT (15 patients) which failed. Patients were treated with a second allo-HSCT after reduced-intensity conditioning (RIC) treatment.  

In the group that had a first auto-HSCT, the average follow-up was 11 months. The one-year overall survival (OS) rate was 66.7% in this group. 59.1% of the patients in this group were alive and disease-free after 1 year. 

In the group that had a first allo-HSCT, the average follow-up was 11 months. The OS rate for this group was 43.3% at one year and 36.1% were alive and disease-free at 1 year. 

Graft-versus-host disease (GVHD) is when the transplanted cells attack the patient's body. It is a complication of HSCT. In the group with a first auto-HSCT transplant, 25% had a short-term GVHD and 41.6% had a long-term GVHD after the second allo-HSCT. In the group that had a first allo-HSCT, 13.2% had short-term GVHD and 40% had long-term GVHD after the second allo-HSCT. 

A period longer than 10 months between transplants was associated with a 73% higher chance of longer OS. The occurrence of long-term GVHD after the second transplant was associated with a 74% higher chance of a longer OS.

The bottom line

This study concluded that a second outpatient allo-HSCT using RIC after a first auto- or allo-HSCT failure or relapse is a good option in patients with leukemia or lymphoma. 

The fine print

This study included a small number of participants with different blood cancers. Also, the results were based on medical records. Information might have been missing. Further studies are needed.

Published By :

Hematological Oncology

Date :

Sep 25, 2020

Original Title :

Outcomes of second hematopoietic stem cell transplantation using reduced-intensity conditioning in an outpatient setting.

click here to get personalized updates